2022 World Conference on Lung Cancer (ePosters)-EP08.02-076. Efficacy and Safety Evaluations of Anlotinib in Patients with Advanced Non-small Cell Lung Cancer Treated with Bevacizumab

EP08.02-076. Efficacy and Safety Evaluations of Anlotinib in Patients with Advanced Non-small Cell Lung Cancer Treated with Bevacizumab

Back to course

Pdf Summary

A study was conducted to evaluate the efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer (NSCLC) who had previously been treated with bevacizumab. The study included patients who had a confirmed diagnosis of metastatic or recurrent NSCLC and had received at least one prior systemic therapy with bevacizumab. Anlotinib, at a dose of 12mg once daily, was administered until disease progression or treatment intolerance. The primary endpoint of the study was overall survival (OS), with secondary endpoints including progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety. <br /><br />The study enrolled a total of 30 patients, with 29 patients included in the evaluation of treatment. The median follow-up period was 12.1 months. Anlotinib demonstrated favorable activity and manageable toxicity in NSCLC patients previously treated with bevacizumab. The most common adverse events reported were fatigue, hypertension, hand-foot syndrome, anorexia, and hypertriglyceridemia, with most being grade one or two. Among the 29 patients, no complete response cases were observed, while 3 patients (10.2%) showed a partial response, 21 patients (72.4%) had stable disease, and 5 patients (17.2%) had progressive disease. The overall response rate was 10.2%, and the disease control rate was 82.7%. The median PFS was 5.6 months, and the median OS was 10.6 months. The overall tolerance of anlotinib treatment was well, with no grade four or five toxicities observed. One patient required a reduction in the dose of anlotinib due to hypertension and headache. <br /><br />In conclusion, anlotinib showed promising efficacy and manageable toxicity in NSCLC patients previously treated with bevacizumab. The study provides evidence for the potential use of anlotinib as a treatment option in this patient population. Further research and clinical trials are needed to validate these findings and establish the optimal use of anlotinib in NSCLC.

Asset Subtitle

Fenge Jiang

Meta Tag

Speaker Fenge Jiang

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

anlotinib

efficacy

safety

NSCLC

bevacizumab

metastatic

PFS

adverse events

clinical trials